LIRAGLUTIDE VS. SITAGLIPTIN AS ADD-ON TO METFORMIN TREATMENT FOR TYPE 2 DIABETES MELLITUS- SHORT TERM COST-PER-CONTROLLED PATIENT IN ITALY
Author(s)
Ramirez de Arellano A1, Montagnoli R2, Ferrario MG3
1Novo Nordisk, Madrid, Spain, 2Novo Nordisk SpA, Rome, Italy, 3Outcomes'10, Castellon, Spain
OBJECTIVES: To estimate the short-term cost per controlled patient with type 2 diabetes mellitus (T2DM) with liraglutide 1.2mg/day vs. sitagliptin 100mg/day in Italy. METHODS: A composite endpoint defined as “HbA1c<7% AND no weight gain AND no hypoglycemia” was adopted to describe the controlled T2DM patient. Based on data from a clinical trial (1860-Lira-DPP4) and a meta-analysis (Zinman et al
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PDB56
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Diabetes/Endocrine/Metabolic Disorders